FG Launches Bi-annual HIV Prevention Injection To Transform Nigeria’s Fight Against New Infections
Princess-Ekwi Ajide
In a country where adherence to daily medication remains a major hurdle in HIV prevention, Nigeria is turning to innovation, introducing a twice-yearly injectable that could redefine how millions protect themselves.
The Federal Government has announced the rollout of Lenacapavir (LEN PrEP), a long-acting injectable drug for the prevention of HIV infection, marking a major milestone in Nigeria’s journey to end AIDS as a public health threat by 2030.
Speaking at a press briefing in Abuja, the Minister of State for Health and Social Welfare, Dr Iziaq Adekunle Salako, said the introduction of Lenacapavir reflects Nigeria’s commitment to adopting cutting-edge, evidence-based solutions to curb new infections and expand access to prevention services.
Lenacapavir, administered once every six months, offers a more convenient and discreet alternative to daily oral pre-exposure prophylaxis (PrEP), particularly for individuals who struggle with adherence due to stigma, access challenges, or lifestyle constraints.
Nigeria has been selected as one of nine early adopter countries by the Global Fund, with about 52,000 doses already secured to kick-start the programme beginning in 2026.
Health authorities say the injectable drug boasts high efficacy, improved convenience, and a safety profile comparable to existing options, making it especially beneficial for key and vulnerable populations at higher risk of HIV infection.
The rollout will begin across eight states, Anambra, Ebonyi, Gombe, Kwara, Akwa Ibom, Cross River, Benue, and the Federal Capital Territory, following extensive planning, regulatory approvals, and capacity-building efforts involving national and international stakeholders.
Dr Salako noted that Lenacapavir will complement, not replace, existing prevention methods such as oral PrEP and Cabotegravir, giving individuals more options tailored to their needs.
Additionally, representatives of the Institute of Human Virology Nigeria (IHVN) described the development as a “game changer,” emphasising that the biannual injection could significantly improve uptake and adherence, especially among populations that face barriers to daily medication.
They added that IHVN is supporting the rollout through integrated service delivery, healthcare worker training, community engagement, supply chain management, and real-time monitoring systems to ensure effective and sustainable implementation.
With Nigeria continuing to record progress in reducing new HIV infections, experts believe the introduction of Lenacapavir could accelerate gains, reduce long-term treatment costs, and bring the country closer to epidemic control.
As preparations intensify for the official launch and facility-level deployment, stakeholders say the success of the initiative will depend on sustained awareness, community trust, and equitable access to resources.
Follow the Savinews Africa channel on WhatsApp: https://whatsapp.com/channel/0029VawgaEL5vKA9Y5XTFg0n
